Read this company snapshot
Daily valuation snapshot
Autolus Therapeutics plc American Depositary Share: source evidence dated 2026-10-09.
- Daily close (USD)
- $1.81
- Market capitalization (USD)
- $481,754,197.4
- Price / earnings (TTM)
- Not reported
- Price / book
- 6.44
The source values and product destination above identify the example to inspect.
What business is this, and what does its dated valuation mean?
Check the market day first. P/E uses trailing earnings; book value and market capitalization answer different questions.
Daily valuation dataset and column definitionsOpen the company research view or ask Aurora to reconcile reporting periods, earnings, debt and the figures behind the valuation.
Research AUTL in the app
Open the company research view or ask Aurora to reconcile reporting periods, earnings, debt and the figures behind the valuation.
Research AUTL in the appKeep reporting dates and units beside the answer, and inspect its original citations.
Company overview
Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases in United Kingdom and internationally. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma. It focuses on developing AUTO5, a preclinical TRBC2 programmed T cell product candidate for the treatment of peripheral T-cell lymphoma. The company was incorporated in 2014 and is headquartered in London, the United Kingdom.
Daily valuation snapshot
See the complete daily valuation snapshot
These values come from the daily market snapshot dated 2026-10-09. TTM means trailing twelve months. Use the market date when comparing AUTL with another company.
Scroll sideways to compare all columns. Select a heading to sort.
| Daily close (USD) | $1.81 |
| Market capitalization (USD) | $481,754,197.4 |
| Price / earnings (TTM) | Not reported |
| Price / book | 6.44 |
No matching rows. Clear the filter to see all records.
Read AUTL's valuation metrics
Company size
Autolus Therapeutics plc American Depositary Share's recorded market capitalization is $481,754,197.4. It measures the market value of the company's equity, rather than its revenue or cash balance.
Price relative to earnings
P/E compares share price with trailing annual earnings per share. For a company with losses, inspect the earnings figures directly rather than treating a negative multiple as a cheap valuation.
Price relative to book equity
AUTL's recorded price-to-book ratio is 6.44. That compares its market equity value with recorded book equity. Examine its business and balance sheet to understand why those values differ.
Research Autolus Therapeutics plc American Depositary Share with Aurora
Use the snapshot above to ask a specific question about AUTL. Ask for the report period and the figures behind the explanation, then compare the answer with the company's business description.
Continue the research
Follow AUTL's ownership disclosures to see who filed a transaction or position and when it became public. To turn a research idea into a strategy, define an entry rule and test its dated observations.